Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Part of paid clinical trials in Fargo, North Dakota.

Sponsor
LAPIX Therapeutics Inc.
Study ID
NCT06982352
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Atopic Dermatitis (AD)
  • Psoriasis (PsO)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LPX-TI641 — DRUG
    Oral administration QD for 28 consecutive days
  • Placebo — DRUG
    Placebo an identical oral formulation without the LPX-TI641.

Study Details

The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.

Key Dates

Start date
Jun 15, 2025
Status verified
Dec 2025
Primary completion
Jan 15, 2026
Completion
Apr 15, 2026

Study Design

Enrollment
48 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Psoriasis
    LPX-TI641 or Placebo
  • Experimental: Atopic dermatitis
    LPX-TI641 or Placebo

Primary Outcome Measure

To evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with PsO and AD. [ Time Frame: 84 days ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Red River Research PartnersFargoNorth Dakota58103-
Clinical Investigations of TexasDallasTexas75075
Sangram Raut, PhD
[email protected]
9725991530

Find similar trials in Fargo, ND

By research site
Red River Research Partners· Fargo, NDClinical Investigations of Texas· Dallas, TX

Related Studies